Nautilus Biotechnology placed its single‑molecule protein analysis system at the Buck Institute for Research on Aging—the first external installation—so Buck researchers can profile tau proteoforms and other neurologic targets locally. Nautilus’ platform uses DNA‑origami functionalized chips to deposit and analyze individual proteins at very high density, enabling detection of proteoform diversity across orders of magnitude. Buck teams plan to use a 12‑antibody probe set to measure hundreds of tau proteoforms and study their role in neurodegeneration. Nautilus framed the deployment as the first step toward an early‑access program for targeted proteomics applications and the move improved its market sentiment, with the company reporting a share price jump on the news.